Johnson & Johnson (JNJ) boosted its sales and profit outlook for the year after reporting second-quarter financial results that beat Wall Street expectations, aided by growth in its pharmaceuticals business.
The company raised its full-year sales guidance of $71.5 billion to $72.2 billion, up from the sweetened forecast of $71.2 billion to $71.9 billion the company issued in April. It also increased its adjusted 2016 earnings guidance to a range of $6.63 to $6.73 per share, up from $6.53 to $6.68.
11:57 Qualcomm says Apple to stop paying royalties, cuts profit forecast23
20:12 Amgen first-quarter profit exceeds Street estimates on lower costs17
17:52 4th Wall Theatre Co.'s 2017-18 season features Pulitzer Prize-winning 'Disgraced'14
23:59 Shares in Takata suspended after reported bankruptcy filing plan18